Skip to main content

Mind Medicine Mindmed Inc(MNMD-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low14.31
Day High15.16
Open:14.86
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Mind Medicine Mindmed Inc

Select a category then submit the form to load news
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Definium Therapeutics Rebrands and Highlights 2026 Pipeline
Tipranks
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Mind Medicine (MNMD)
Zacks Investment Research
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
Tipranks
MindMed Expands Into Autism: What Investors Should Know About the New MM402 Trial
Tipranks
Mind Medicine (MNMD) Receives a Rating Update from a Top Analyst
MarketBeat
MarketBeat’s Top 5 Rated Small-Cap Stocks
MarketBeat.com
Business Wire
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
Zacks Investment Research
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
Business Wire
MindMed Announces New Employee Inducement Grant
Business Wire
MindMed Announces New Employee Inducement Grants
Tipranks
MindMed’s Earnings Call: Positive Outlook Amid Financial Challenges
Tipranks
H.C. Wainwright Sticks to Its Buy Rating for Mind Medicine (MNMD)
Tipranks
Mind Medicine (MNMD) Receives a Buy from Evercore ISI
Tipranks
Oppenheimer Sticks to Its Buy Rating for Mind Medicine (MNMD)
Tipranks
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Mind Medicine (MNMD) and Tandem Diabetes Care (TNDM)
Tipranks
MindMed Reports Q3 2025 Financial Progress
Tipranks
Mind Medicine Reports Q3 2025 Financial Results
Motley Fool
MindMed (MNMD) Q3 2025 Earnings Call Transcript
Business Wire
MindMed Reports Q3 2025 Financial Results and Business Updates
Business Wire
MindMed to Participate in Upcoming Investor Conferences
Tipranks
MindMed Issues Inducement Grants to New Employees
Tipranks
MindMed Secures $259 Million in Public Offering to Advance Brain Health Innovations
Business Wire
MindMed Announces New Employee Inducement Grant
Business Wire
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Tipranks
Mind Medicine Completes Successful Public Offering
Tipranks
MindMed Highlights Strategic Focus in New Presentation
Business Wire
MindMed to Report Q3 2025 Financial Results on November 6, 2025
Business Wire
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
Business Wire
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
Tipranks
Mind Medicine’s Phase 3 Trial of MM120: A Potential Breakthrough for Depression Treatment
Tipranks
Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD) and OS Therapies Incorporated (OSTX)

Profile

Mind Medicine Inc. is a clinical-stage psychedelic medicine biotech company. It discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. Mind Medicine Inc. is based in New York, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.